VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 8, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has reached an agreement with Tincali Tech Consulting ("Tincali"), located in the United Kingdom, to assist ALDA with regulatory matters in the EU. The first task undertaken by Tincali is a competitive analysis of the UK market for hand sanitizers. Subsequently, Tincali will define the process required for ALDA to market T36(R) Personal Disinfectant in both the EU and the Middle East using the existing EU registration. This product will be marketed using the new "brand" that is being developed by Cowie and Fox. Tincali will then assist ALDA in coordinating the clinical trials that are required for EU, US and Canadian registration of ALDA's therapeutic products.

Dr. Terrance Owen, President & CEO, states, "We are pleased to have Tincali acting on ALDA's behalf in Europe. To accomplish the registration of ALDA's therapeutic products in a timely and efficient manner requires a physical presence in the territory. Now that we have an EU-based consultant, we hope to see significant progress towards marketing ALDA's T36(R) Personal Disinfectant and the new antiseptic hand cleanser in Europe and the Middle East."

About Tincali Tech Consulting

Tincali is a UK-based consulting group that provides professional services to pharmaceutical companies, including evaluation of potential new products, acquisition of technologies, product commercialization planning, regulatory assessment and market analysis. The Managing Director of Tincali, Dr. Carlos Pittol, has over 12 years of business experience, following completion of a PhD in Chemistry in the UK and a Postdoctoral Research Fellowship in pharmaceutical chemistry at the University of Toronto.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.